Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases

Chest

Volumn 123, Issue 6, 2003, Pages 2001-2006

  Nakayama, Mika ^a   Satoh, Hiroaki ^a   Ishikawa, Hiroichi ^b   Fujiwara, Masachika ^c   Kamma, Hiroshi ^a   Ohtsuka, Morio ^a   Sekizawa, Kiyohisa ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

^c Kensei General Hospital   (Japan)

Author keywords

Cytokeratin 19 fragment; Immunochemistry; Nonmalignant respiratory diseases; Serum; Western blotting

Indexed keywords

CYTOKERATIN 19 FRAGMENT;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHIECTASIS; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIAGNOSTIC VALUE; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS PROTEINOSIS; LUNG CANCER; LUNG DISEASE; LUNG FIBROSIS; LUNG MYCOSIS; LUNG SARCOIDOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PNEUMOCONIOSIS; PNEUMONIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

EID: 0038805330     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.6.2001     Document Type: Article

References (22)

1. Moll R, Franke WW, Schiller DL. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31:11-24
2. Fuchs E. Keratins as biochemical markers of epithelial differentiation. Trends Genet 1983; 4:277-281
3. Coulombe PA. The cellular biology of keratins: beginning a new era. Curr Opin Cell Biol 1993; 5:17-29
4. Steinert PM Structure, function, and dynamics of keratin intermediate filaments. J Invest Dermatol 1993; 100:729-734
5. Iyonaga K, Miyafuji M, Suga M, et al. Alterations in cytokeratin expression by the alveolar lining epithelial cells in lung tissue from patients with idiopathic pulmonary fibrosis. J Pathol 1997; 182:217-224
6. Pujol JL, Grenier J, Daures JP, et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immuno-radiometric assay as a marker of lung cancer. Cancer Res 1993; 53:61-66
7. Muraki M, Tohda Y, Iwanaga T, et al. Assessment of serum CYFBA 21-1 in lung cancer. Cancer 1996; 77:1274-1277
8. Lai RS, Hsu HK, Lu JY, et al. CYFRA 21-1 enzyme-linked immunosorbent assay: evaluation as a tumor marker in non-small cell lung cancer. Chest 1996; 109:995-1000
9. Sugama Y, Kitamura S, Kawai T, et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res 1994; 85: 1178-1184
10. Matsubara Y, Iwashita T, Ishimatsu Y, et al. Elevation of CYFBA 21-1 and ProGRP in serum and bronchoalveolar lavage fluid of patients with benign lung disease [in Japanese with English abstract]. Nihon Kokyuki Gakkai Zasshi 2000; 38:659-664
11. Dobashi N, Fujita J, Ohtsuki Y, et al. Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia. Eur Respir J 1999; 14:574-578
12. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment; international consensus statement. Am J Respir Crit Care Med 2000; 161:646-664
13. Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-347
14. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292:344-347
15. Vitalli C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjogren's syndrome: results of a prospective concerned action supported by the European Community. Arthritis Rheum 1993; 36:340-347
16. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-590
17. Kasugawa R. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasugawa R, Sharp GC, eds. Mixed connective tissue disease and anti-nuclear antibodies. Amsterdam, the Netherlands: Excerpta Medica, 1987; 41-47
18. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685
20. Fujiwara M, Satoh H, Fujimoto M, et al. Lung cancer cell line producing cytokeratin 19 fragment and sialyl Lewis X-i antigen. Anticancer Res 1998; 18:1043-1046
21. Pasanen PA, Eskelinen M, Psrtsnen K, et al. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer: results from a prospective study. Br J Cancer 1993; 67:852-855
22. Nakamura H, Abe S, Shibata Y, et al. Elevated levels of cytokeratin 19 in the bronchoalveolar lavage fluid of patients with chronic airway inflammatory diseases: a specific marker for bronchial epithelial injury Am J Respir Crit Care Med 1997; 155:1217-1221